Details

Autor(en) / Beteiligte

• Bhimraj, Adarsh
• Morgan, Rebecca L
• Shumaker, Amy Hirsch
• Baden, Lindsey
• Chi-Chung Cheng, Vincent
• Edwards, Kathryn M
• Gandhi, Rajesh T
• Gallagher, Jason C
• Muller, William J
• O’Horo, John C
• Shoham, Shmuel
• Wollins, Dana Swartzberg
• Falck-Ytter, Yngve

Titel

Lessons Learned from Coronavirus Disease 2019 (COVID-19) Therapies: Critical Perspectives From the Infectious Diseases Society of America (IDSA) COVID-19 Treatment Guideline Panel

Ist Teil von

• Clinical infectious diseases, 2022-05, Vol.74 (9), p.1691-1695

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2022

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Despite the challenges of the pandemic, there has been substantial progress with coronavirus disease 2019 (COVID-19) therapies. Pivotal COVID-19 trials like SOLIDARITY, RECOVERY, and ACCT-1 were rapidly conducted and data disseminated to support effective therapies. However, critical shortcomings remain on trial conduct, dissemination and interpretation of study results, and regulatory guidance in pandemic settings. The lessons that we learned have implications for both the current pandemic and future emerging infectious diseases. There is a need for establishing and standardizing clinical meaningful outcomes in therapeutic trials and for targeting defined populations and phenotypes that will most benefit from specific therapies. Standardized processes should be established for rapid and critical data review and dissemination to ensure scientific integrity. Clarity around the evidence standards needed for issuance of both emergency use authorization (EUA) and biologic license application (BLA) should be established and an infrastructure for executing rapid trials in epidemic settings maintained. Although there has been substantial progress with coronavirus disease 2019 (COVID-19) therapies, there have been critical shortcomings in the conduct and execution of clinical trials, dissemination of results, and standardization of therapies. These critical issues need to be discussed and addressed.